Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Immatics ( (IMTX) ) just unveiled an announcement.
On December 8, 2025, Immatics N.V. completed an offering of 12,500,000 ordinary shares, raising approximately $116.5 million after expenses. The proceeds will support the company’s research and development pipeline, manufacturing, and potential commercialization of its product candidates. This strategic move is expected to bolster Immatics’ position in the biopharmaceutical industry, enhancing its operational capabilities and market presence.
The most recent analyst rating on (IMTX) stock is a Buy with a $23.00 price target. To see the full list of analyst forecasts on Immatics stock, see the IMTX Stock Forecast page.
Spark’s Take on IMTX Stock
According to Spark, TipRanks’ AI Analyst, IMTX is a Neutral.
Immatics’ overall stock score is primarily influenced by its financial performance challenges, including inconsistent revenue growth and profitability. Positive technical indicators provide some support, suggesting potential short-term bullish momentum. However, the negative P/E ratio and lack of dividend yield highlight valuation concerns. The absence of earnings call data and corporate events limits additional insights.
To see Spark’s full report on IMTX stock, click here.
More about Immatics
Immatics is a clinical-stage biopharmaceutical company that leads in precision targeting of PRAME, a target expressed in over 50 cancers. The company focuses on developing TCR T-cell therapies and TCR bispecifics, forming the broadest PRAME franchise with numerous indications and modalities.
Average Trading Volume: 796,202
Technical Sentiment Signal: Buy
Current Market Cap: $1.24B
See more data about IMTX stock on TipRanks’ Stock Analysis page.